骨桥蛋白和趋化因子受体4在卵巢肿瘤组织中的表达及其意义

doi:10.13481/j.1671-587x.20150617

摘要/Abstract

摘要：

目的:分析骨桥蛋白(OPN)和趋化因子受体4(CXCR4)在不同卵巢组织中的表达,探讨二者在卵巢癌的发生、发展和转移过程中的作用。方法:选取正常卵巢组织(20例)、卵巢良性上皮性肿瘤组织(20例)和上皮性卵巢癌组织(40例),采用免疫组织化学SP法检测不同卵巢组织中OPN和CXCR4表达,分析不同临床特征上皮性卵巢癌组织中OPN蛋白和CXCR4蛋白表达率。结果: OPN在上皮性卵巢癌组织的阳性表达率高于在正常卵巢组织和良性卵巢肿瘤组织表达率,不同分化程度(G₁、G₂和G₃期)上皮性卵巢癌组织阳性表达率组间比较差异均有统计学意义(P<0.05),Ⅲ-Ⅳ期上皮性卵巢癌组织中OPN阳性表达率明显高于Ⅰ-Ⅱ期组(P<0.05),在不同组织学分型上皮性卵巢癌组织(卵巢浆液性囊腺癌、卵巢黏液性囊腺癌和卵巢子宫内膜样癌)中OPN阳性表达率比较差异无统计学意义(P>0.05)。CXCR4在正常卵巢组织及卵巢良性肿瘤组织中均无阳性表达,在上皮性卵巢癌组织中呈阳性表达。CXCR4在上皮性卵巢癌不同病理分级(高分化G₁、中分化G₂和低分化G₃)、不同临床分期(Ⅰ-Ⅱ期、Ⅲ-Ⅳ期)、不同组织学分型(浆液性囊腺癌、黏液性囊腺癌和子宫内膜样癌)组织中阳性表达率比较差异无统计学意义(P>0.05)。结论:OPN和CXCR4在卵巢肿瘤细胞中表达水平与肿瘤细胞的恶性程度具有一定关联,提示OPN和CXCR4表达通路可能成为卵巢癌治疗的一个新靶点。

关键词: 骨桥蛋白, 趋化因子受体4蛋白, 卵巢肿瘤, 免疫组织化学

Abstract:

Objective To analyze the expressions of osteopontin(OPN) and chemokine(CXC-subfamily)receptor 4(CXCR4) in different ovarian tissues,and to explore the role of OPN and CXCR4 in occurrence,development and metastasis of human ovarian cancer. Methods The expressions of OPN and CXCR4 in normal ovarian tissue(n=20),benign ovarian epithelial tumor(n=20) and epithelial ovarian cancers tissues(n=40) were detected by immunohistochemical SP method, and the expression rates of OPN and CXCR4 in epithelial ovarian cancer tissue with different clinical characteristics were analyzed. Results The positive expressions rate of OPN in epithelial ovarian cancer tissue was significantly higher than those in normal ovarian tissue and benign ovarian tumor tissue,and there were significant differences in the positive expression rates of OPN between different pathological stages (G₁,G₂,G₃) of epithelial ovarian cancer (P<0.05).Meanwhile,the positive expression rate of OPN in Ⅲ-Ⅳ epithelial ovarian cancer tissue was significantly higher than that in Ⅰ-Ⅱ epithelial ovarian cancer tissue (P<0.05).However,there were no significant differences of the positive expression rates of OPN among different histological types of epithelial ovarian cancer tissue (P>0.05).There was no positive expression of CXCR4 protein in normal ovarian tissue and benign ovarian tumor tissues,but there was positive expression in epithelial ovarian cancer tissue.Besides,the expressions of CXCR4 protein were not significantly different among different pathological grades,different clinical stages and different histological types (P>0.05). Conclusion The OPN and CXCR4 expression levels are correlated with the degrees of malignancy in epithelial ovarian tumor,therefore the CXCR4 and OPN expression pathways may be the new targets for ovarian cancer therapy.

Key words: osteopontin, chemokine(CXC-subfamily)receptor 4, ovarian neoplasms, immunohistochemistry

中图分类号:

R737.71

王堃, 张爱臣, 盛敏佳, 潘颖, 佟玲玲, 孙小淳. 骨桥蛋白和趋化因子受体4在卵巢肿瘤组织中的表达及其意义[J]. 吉林大学学报(医学版), 2015, 41(06): 1186-1189.

WANG Kun, ZHANG Aichen, SHENG Minjia, PAN Ying, TONG Lingling, SUN Xiaochun. Expressions of OPN and CXCR4 in human epithelial ovarian cancer tissueand their clinical significances[J]. Journal of Jilin University Medicine Edition, 2015, 41(06): 1186-1189.

参考文献

[1] Ma GF,Li YH,Gao CX, et al. Expression and clinical significance of osteopontin in gastric cancer[J].Jiangsu Med J,2014,40( 2) :169-171.

[2] Weber GF,Lett GS,Haubein NC.Osteopontin is a marker for cancer aggressiveness and patient survival[J].BrJCancer,2010,103(6):861-869.

[3] Hwang J,Na S,Lee H,et al.Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer[J].J Gynecol Oncol,2009,20(3):169-175.

[4] Yeatman TJ,Chambers AF.Osteopontin and colon cancer progression[J].Clin Exp Metastasis,2003,20(1):85-90.

[5] Graham NA,Graeber TG.Complexity of metastasis-associated SDF-1 ligand signaling in breast cancer stem cells[J]. Proc Natl Acad Sci USA,2014,111(21): 7503-7504.

[6] Ding G,Wang L,Xu H, et al. Mesenchymal stem cells in prostate cancer have higher expressions of SDF-1,CXCR4 and VEGF[J].Gen Physiol Biophys,2013,32(2): 245-250.

[7] 黄天臣,邱新光.血清骨桥蛋白检测对预测胃癌转移复发的意义[J].武汉大学学报:医学版,2013,34(2):280-284.

[8] Wai PY,Kuo PC.The role of Osteopontin in tumor etastasis[J].Surg Res,2004,121(2):228-241.

[9] Ray P,Lewin SA,Mihalko LA, et al. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4[J]. Neoplasia,2011,13(12):1152-1161.

[10] Helbig G,Christopherson KW,Bhat-Nakshatri P,et al.NF-kappaB promotes breast cancer cellmigration and metastasis by inducing the exp-ression of the chemokine receptor CXCR4 [J].J Biol Chem,2003,278 (24): 21631-21638.

[11] Ganjur K,Brubaker SA,Meyer J,et al.The alphachemokine,stromal cell-derived factor-1alpha,binds to the transmem brane G-protein-coup led CXCR4 receptor and activates multiple signal transduction pathWays[J].J Biol Chem,1998,273 (36):23169-23175.

[12] Rosen DG,Wang L,Atkinson JN,et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer [J].Gynecol Oncol,2005,99(2) :267-277.

[13] Kim JH,Skates SJ,Uede T,et al.Osteopontin as a potential diagnostic biomarker for ovarian cancer [J].JAMA,2002,287(13):1671-1679.

[14] Coppola D,Szabo M,Boulware D,et al.Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies[J].Clin Cancer Res,2004,10(1):184-190.

[15] Matsuura M,Suzuki T,Saito T.Osteopont in is a new target molecule for ovarian clear cell carcinoma therapy[J].Cancer Sci,2010,101(8): 1828-1833.

[16] 周良学,游潮. SDF-1 /CXCR4 生物轴与肿瘤研究进展[J]. 西部医学, 2009, 21(11): 1993-1995.

[17] RetzMM,S idhu SS,B laveri E,et al.CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells[J].IntJCancer,2005,114 (2): 182-189.

[18] Ottaiano A,Franco R,Aiello Talamanca A,et al.Overexp ression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse instage Ⅱ-Ⅲ colorectal cancer patients [J].Clin Cancer Res,2006,12 (9): 2795-2803.